WednesdayJan 18, 2023 10:35 am

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel (“Kernel”). The study was designed to evaluate Kernel’s Flow(R) wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The results from the feasibility study are very promising and provide further insights into the potential of this cutting-edge wearable technology to quantify neural activity and changes in brain biomarkers during the administration of psychedelics. The possibility of using this technology to develop a predictive tool to aid…

Continue Reading

TuesdayJan 17, 2023 11:11 am

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Provides Strategic Update in Annual Shareholder Letter

Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka has released an annual letter to shareholders. The detailed letter talks about company highlights throughout the year, including the fact that, despite challenges such as global supply chain disruptions and threatening inflation, “Lexaria continues to navigate well and is focused on those things it can control such as applied R&D designed to entice others to work with us commercially. . . . [The company] has not terminated any staff and in fact our in-house team as well as our external consultant head-count has never been higher, in order to conduct and [analyze] an…

Continue Reading

ThursdayJan 12, 2023 2:29 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patented DehydraTECH(TM) drug delivery technology. “For Lexaria, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought Lexaria closer to realizing this goal, with the company initiating a slew of research programs, many of which it has already completed. Moreover, its intellectual property (‘IP’) portfolio received additional patent protection in different jurisdictions around the world. Lexaria also…

Continue Reading

ThursdayJan 12, 2023 1:10 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated phase 1b /2 trial evaluating the company’s novel anthracycline, Berubicin. The study, titled “Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas,” will be conducted at the Pomeranian Medical University (“PUM”) in Szczecin, Poland. “Based on the data seen to date, Berubicin has continued to demonstrate an overall safety profile more favorable than other known anthracyclines and we remain encouraged by its potential.…

Continue Reading

ThursdayJan 12, 2023 12:46 pm

TinyGemsBreaks – Vision Energy Corp. (VENG) Issues Update on Recent Market Activity

Vision Energy (OTC: VENG) (the “Company”) today issued statements regarding recent removal from the OTCQB Market. On Dec. 6, 2022, Vision Energy was informed by the OTC Markets Group Inc. of certain promotional material that encouraged investors to purchase or trade the Company’s common stock. On Jan. 10, 2022, the Company was informed that, due to the ongoing promotional campaign, it would be moved from the OTCQB Market to the Pink Market effective Jan. 11, 2023. As detailed in the update, Vision Energy is and continues to be committed to compliance with OTC Markets’ policy on stock promotion and the…

Continue Reading

ThursdayJan 12, 2023 11:15 am

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Moves to Acquire MeridianBet Group

Golden Matrix Group (NASDAQ: GMGI) is a developer, licensor and global operator of online gaming and eCommerce platforms, systems and gaming content. The company today announced its entry into a definitive acquisition agreement pursuant to which it has agreed to acquire MeridianBet Group and its related companies in a cash and stock transaction valued at approximately $300 million. MeridianBet is Southeast Europe’s leading business-to-consumer (“B2C”) sports betting and gaming group with headquarters in Malta, operating in multiple markets across Europe, Africa and Latin America. “We are thrilled to announce our entry into a purchase agreement with the shareholders of MeridianBet…

Continue Reading

ThursdayJan 12, 2023 10:34 am

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for CYB004 — its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule. “Based on preclinical data, CYB004 has shown promise in treating anxiety disorders. About half of people suffering from depression are also burdened with GAD, which makes the need for more effective treatment options for GAD even more urgent,” said Cybin CEO Doug Drysdale. “Since the pandemic, the prevalence of depression and…

Continue Reading

ThursdayJan 12, 2023 10:14 am

TinyGemsBreaks — Cepton Inc. (NASDAQ: CPTN) Announces Approval of Preferred Stock Issue by Shareholders

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, reported that its stockholders approved the company’s proposal to issue 100,000 shares of Series A Convertible Preferred Stock to Koito Manufacturing Co. Ltd.  The issuance, which would be for $100 million, is based on the terms of an investment agreement between the two companies that was signed on Oct. 27, 2022. According to the announcement, the investment should close on Jan. 19, 2023. Shareholders voted on the proposal during Cepton’s recent special meeting of shareholders, which was held on Jan. 11, 2023. To view the full press release,…

Continue Reading

WednesdayJan 11, 2023 12:03 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine

Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune initiated the GMP manufacturing of drug candidate ADI(TM)-100 for purposes of initiating human trials. The trial will be performed in autoimmune diseases, with psoriasis as the first indication to be studied. Adimune’s nucleic acid-based technology, ADI(TM), has shown in preclinical studies the ability to restore/induce immune tolerance…

Continue Reading

TuesdayJan 10, 2023 12:26 pm

TinyGemsBreaks – Vision Energy Corp. (VENG) Incorporates Dutch Subsidiaries

Vision Energy (OTCQB: VENG), a forward-looking energy company developing carbon reduced solutions for the commercial, industrial and transportation sector, has incorporated new Dutch subsidiaries. These incorporations are designed to accommodate strategic initiatives for prospective partners, operators and launching customers for VENG’s integrated Green Energy Hub development in North Sea Port of Vlissingen, the Netherlands. According to the announcement, Vision Energy incorporated Vision Hydrogen BV as a project development company to develop, own and operate its planned Ammonia Cracking Facility. The facility will be used for back-cracking imported green ammonia to hydrogen gas as a service and will be combined with the…

Continue Reading

Contact us: (512) 354-7000